Pacira ((PCRX)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pacira Pharmaceuticals, Inc. is currently recruiting for a Phase 3 clinical study titled ‘A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis.’ The primary objective is to assess the efficacy of ZILRETTA on pain relief following an intra-articular injection compared to a normal saline placebo. Secondary objectives include comparing ZILRETTA’s efficacy to triamcinolone acetonide injectable suspension (TCA-IR) and evaluating its safety.
The study tests ZILRETTA, an intra-articular injection designed to alleviate pain in patients with glenohumeral osteoarthritis. It aims to provide a long-lasting pain relief option compared to existing treatments.
This interventional study is randomized with a parallel assignment model. It employs single masking, where the investigator is blinded, ensuring unbiased results. The primary purpose is treatment-focused, aiming to establish ZILRETTA as a viable pain management option.
The study began on February 13, 2024, with primary completion expected in 2025. The last update was submitted on May 19, 2025, indicating ongoing progress and adjustments as necessary.
Pacira’s study could significantly impact its stock performance, as positive results may enhance investor confidence and market position against competitors. The success of ZILRETTA could potentially disrupt the osteoarthritis treatment market, offering a new alternative for pain management.
The study is ongoing, with further details available on the ClinicalTrials portal.